Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bf7eb9ac8fca6067cda90d4ca96d0afe9> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bf7eb9ac8fca6067cda90d4ca96d0afe9 NCIT_P378 "NCI" @default.
- Bf7eb9ac8fca6067cda90d4ca96d0afe9 type Axiom @default.
- Bf7eb9ac8fca6067cda90d4ca96d0afe9 annotatedProperty IAO_0000115 @default.
- Bf7eb9ac8fca6067cda90d4ca96d0afe9 annotatedSource NCIT_C1340 @default.
- Bf7eb9ac8fca6067cda90d4ca96d0afe9 annotatedTarget "A semisynthetic derivative of the antineoplastic anthracycline antibiotic doxorubicin. With a mechanism of action that appears to differ from doxorubicin, valrubicin is converted intracytoplasmically into N-trifluoroacetyladriamycin, which interacts with topoisomerase II, stabilizing the complex between the enzyme and DNA; consequently, DNA replication and repair and RNA and protein synthesis are inhibited and the cell cycle is arrested in the G2 phase. In addition, this agent accumulates in the cell cytoplasm where it inhibits protein kinase C (PKC). Valrubicin is less cardiotoxic than doxorubicin when administered systemically; applied topically, this agent shows excellent tissue penetration. Structurally, the trifluoro-acetyl moiety on the amino group of the glycoside and the valerate moiety appear to result in a lipophilicity that is greater than of doxorubicin, resulting in increased intracytoplasmic concentrations." @default.